Pumitamig

• A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending
  2025-523576-23-00 Phase III 14 countries Bristol-Myers Squibb Services Unlimited Company
• A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Pending
  2025-523586-18-00 Phase III 16 countries Bristol-Myers Squibb Services Unlimited Company
• A Phase 1/2 Study of Pumitamig alone or in Combination with Ipilimumab in First-Line HCC Recruiting
  2025-523602-33-00 Phase I/II 5 countries Bristol-Myers Squibb Services Unlimited Company
• Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Previously Untreated Advanced or Me… Recruiting
  2025-523263-37-00 Phase II/III 6 countries Bristol-Myers Squibb Services Unlimited Company
• Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Previously Untreated, Unresectable, or Met… Recruiting
  2025-523224-45-00 Phase II/III 11 countries Bristol-Myers Squibb Services Unlimited Company
• A clinical study to test if an investigational treatment called BNT314 when used in combination with another investigational treatment pumit… Recruiting
  2025-521768-36-00 Phase I/II 2 countries BioNTech SE
• A clinical study to test if an investigational treatment called BNT326 is safe and potentially beneficial when used alone or in combination … Recruiting
  2024-517261-16-00 Phase I/II 4 countries BioNTech SE

Showing 1–7 of 7 trials